These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25275078)

  • 41. Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium.
    Hainsworth JD; Spigel DR; Greco FA; Shipley DL; Peyton J; Rubin M; Stipanov M; Meluch A
    Cancer J; 2011; 17(5):267-72. PubMed ID: 21952273
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Katori H; Tsukuda M; Taguchi T
    Cancer Chemother Pharmacol; 2007 May; 59(6):789-94. PubMed ID: 17053926
    [TBL] [Abstract][Full Text] [Related]  

  • 43. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G
    Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Docetaxel in squamous cell cancer of the head and neck.
    Posner MR
    Anticancer Drugs; 2001 Feb; 12 Suppl 1():S21-4. PubMed ID: 11340900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
    Li SH; Lin WC; Huang TL; Chen CH; Chiu TJ; Fang FM; Huang WT; Hsu CM; Luo SD; Lai CC; Su YY; Chuang HC; Chien CY
    Head Neck; 2016 Apr; 38 Suppl 1():E844-52. PubMed ID: 25917382
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictive Factors for Completion of TPF Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer.
    Nakano K; Seto A; Sasaki T; Shimbashi W; Fukushima H; Yonekawa H; Mitani H; Takahashi S
    Anticancer Res; 2019 Aug; 39(8):4337-4342. PubMed ID: 31366527
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy.
    Lowe NM; Kershaw LE; Bernstein JM; Withey SB; Mais K; Homer JJ; Slevin NJ; Bonington SC; Carrington BM; West CM
    PLoS One; 2018; 13(3):e0194841. PubMed ID: 29590180
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: a subset analysis of the Head and Neck Contracts Program.
    Jacobs C; Makuch R
    J Clin Oncol; 1990 May; 8(5):838-47. PubMed ID: 2185340
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Induction chemotherapy in nonlaryngeal human papilloma virus-negative high-risk head and neck cancer: a real-world experience.
    Mezi S; Pomati G; Botticelli A; Roberto M; Cerbelli B; Cirillo A; Di Gioia C; Corsi A; Vullo F; De Vincentiis M; Polimeni A; Tombolini V; Valentini V; Marchetti P
    Anticancer Drugs; 2020 Nov; 31(10):1074-1083. PubMed ID: 32932276
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A multicenter randomized phase II trial of hyperthermia combined with TPF induction chemotherapy compared with TPF induction chemotherapy in locally advanced resectable oral squamous cell carcinoma.
    Ren G; Ju H; Wu Y; Song H; Ma X; Ge M; Qiu W; Chen Y; He Y; Zhuang Q; Meng J; Guo W
    Int J Hyperthermia; 2021; 38(1):939-947. PubMed ID: 34134574
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers.
    Bernadach M; Lapeyre M; Dillies AF; Miroir J; Casile M; Moreau J; Molnar I; Ginzac A; Pham-Dang N; Saroul N; Durando X; Biau J
    BMC Cancer; 2021 Apr; 21(1):360. PubMed ID: 33827483
    [TBL] [Abstract][Full Text] [Related]  

  • 52. End points for new agents in induction chemotherapy for locally advanced head and neck cancers.
    Monnerat C; Faivre S; Temam S; Bourhis J; Raymond E
    Ann Oncol; 2002 Jul; 13(7):995-1006. PubMed ID: 12176777
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Empowering induction therapy for locally advanced head and neck cancer.
    Argiris A; Karamouzis MV
    Ann Oncol; 2011 Apr; 22(4):773-781. PubMed ID: 20864569
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neoadjuvant chemotherapy for locally advanced squamous cancers of the head and neck: current status and future prospects.
    Chandana SR; Conley BA
    Curr Opin Oncol; 2009 May; 21(3):218-23. PubMed ID: 19370805
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Role of induction chemotherapy in head and neck cancer: Cons].
    Huguet F; Schick U; Pointreau Y
    Cancer Radiother; 2017 Oct; 21(6-7):510-514. PubMed ID: 28869196
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DNA analysis as a predictor of the outcome of induction chemotherapy in advanced head and neck carcinomas.
    Tennvall J; Wennerberg J; Anderson H; Baldetorp B; Fernö M; Willén R
    Arch Otolaryngol Head Neck Surg; 1993 Aug; 119(8):867-70. PubMed ID: 8343250
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A retrospective study of treatment for curative synchronous double primary cancers of the head and neck and the esophagus.
    Okamoto T; Katada C; Komori S; Yamashita K; Miyamoto S; Kano K; Seino Y; Hosono H; Matsuba H; Moriya H; Sugawara M; Azuma M; Ishiyama H; Tanabe S; Hayakawa K; Koizumi W; Okamoto M; Yamashita T
    Auris Nasus Larynx; 2018 Oct; 45(5):1053-1060. PubMed ID: 29752155
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Volumetric regression ratio of the primary tumor and metastatic lymph nodes after induction chemotherapy predicts overall survival in head and neck squamous cell carcinoma: a retrospective analysis.
    Elicin O; Schmucking M; Bromme J; Rauch D; Ambarcioglu P; Plasswilm L; Geretschlager A; Ghadjar P; Giger R; Aebersold DM
    J BUON; 2016; 21(1):175-81. PubMed ID: 27061546
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phospholipase C gamma 1 is a potential prognostic biomarker for patients with locally advanced and resectable oral squamous cell carcinoma.
    Zhu D; Tan Y; Yang X; Qiao J; Yu C; Wang L; Li J; Zhang Z; Zhong L
    Int J Oral Maxillofac Surg; 2014 Dec; 43(12):1418-26. PubMed ID: 25085076
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer.
    Melchardt T; Hufnagl C; Magnes T; Weiss L; Hutarew G; Neureiter D; Schlattau A; Moser G; Gaggl A; Tränkenschuh W; Greil R; Egle A
    BMC Cancer; 2015 Oct; 15():725. PubMed ID: 26475344
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.